You are here

BioMEMS solutions for the point of care detection of cardiac biomarkers

Mazher-Iqbal Mohammed, Marc Desmulliez, Sir Keith Fox and Colin Campbell
Cardiovascular disease (CVD) accounts for approximately half of all the deaths within the Western World and costs the European Union approximately 192 billion Euros per year. Cardiac biomarkers are crucial in the triage and management of a range of cardiac related conditions where time delay has a major impact on short and longer-term outcomes and health of a patient. The elevation of specific cardiac biomarkers above clinically established baselines provides the clinician with information on the CVD related to a particular set of symptoms. Current clinical practices are failing to attain internationally recognised result turn-around times for diagnostic assays, delaying thereby initial treatment and increasing likelihood of patient mortality. This project aims at creating fully automated and complete PoC lab-on-a-chip device capable of detecting cardiac markers with high sensitivity and specificity from whole blood permitting a reduced diagnosis time for CVD related conditions. The primary emphases of this device will be on the integration of a high sensitivity biosensors within a microfluidic structure and the inclusion of integrated ‘on-chip’ optical components, to increase the detection sensitivity of the device compared to existing commercial PoC devices. The device envisaged will serve as a disposable module that will operate with a bespoke low-power, portable fluorescence reader suitable for PoC applications. The envisaged prototype will negate the requirements for alternative, more complex clinical examinations and will translate into financial savings and reduced turn-around time when implemented within a hospital and primary care setting, whilst also increasing the quality of patient care.

     Cardiovascular disease (CVD) accounts for approximately half of all the deaths within the Western World and costs the European Union approximately 192 billion Euros per year. Cardiac biomarkers are crucial in the triage and management of a range of cardiac related conditions where time delay has a major impact on short and longer-term outcomes and health of a patient.  The elevation of specific cardiac biomarkers above clinically established baselines provides the clinician with information on the CVD related to a particular set of symptoms. Current clinical practices are failing to attain internationally recognised result turn-around times for diagnostic assays, delaying thereby initial treatment and increasing likelihood of patient mortality.
     This project aims at creating fully automated and complete PoC lab-on-a-chip device capable of detecting cardiac markers with high sensitivity and specificity from whole blood permitting a reduced diagnosis time for CVD related conditions.  The primary emphases of this device will be on the integration of a high sensitivity biosensors within a microfluidic structure and the inclusion of integrated ‘on-chip’ optical components, to increase the detection sensitivity of the device compared to existing commercial PoC devices. The device envisaged will serve as a disposable module that will operate with a bespoke low-power, portable fluorescence reader suitable for PoC applications. The envisaged prototype will negate the requirements for alternative, more complex clinical examinations and will translate into financial savings and reduced turn-around time when implemented within a hospital and primary care setting, whilst also increasing the quality of patient care.